September 02, 2010
ImmunoGen, Inc. Announces Webcast of Presentations at Multiple Investor Conferences in September

WALTHAM, Mass., Sep 02, 2010 (BUSINESS WIRE) --

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Company management will present at multiple investor conferences this month. The live webcast of each presentation can be accessed through the "Investor Information" section of the Company's website,; a replay of each presentation will be available for one week.

  • 2010 Morgan Stanley Global Healthcare Unplugged Conference
    8:00 a.m. EDT on September 13, 2010 in New York, NY
    Presenter: Daniel Junius, President and CEO
  • Stifel Nicolaus 2010 Healthcare Conference
    11:30 a.m. EDT on September 15, 2010 in Boston, MA
    Presenter: Gregory Perry, Senior Vice President and CFO
  • Bank of America Merrill Lynch Global Healthcare Conference 2010
    1:00 p.m. BST (8:00 a.m. EDT) on September 16, 2010 in London,England
    Presenter: Daniel Junius, President and CEO
  • UBS Global Life Sciences Conference
    12:00 p.m. EDT on September 20, 2010 inNew York, NY
    Presenter: Gregory Perry, Senior Vice President and CFO

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer cell-killing agents. The Company's Targeted Antibody Payload (TAP) technology uses engineered antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor targets. Product candidates are in development through the Company's own product programs and through ImmunoGen's collaborations with Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, T-DM1, is in Phase III testing through the Company's collaboration with Genentech.

SOURCE: ImmunoGen, Inc.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
For Media:
Yates Public Relations
Kathryn Morris, 914-204-6412



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?